Abstract：
Adjuvants are of critical value in vaccine development as they act on enhancing immunogenicity of antigen and inducing long-lasting immunity. However, there are only a few adjuvants that have been approved for clinical use, which highlights the need for exploring and developing new adjuvants to meet the growing demand for vaccination. Recently, emerging evidence demonstrates that the cGAS-STING pathway orchestrates innate and adaptive immunity by generating type I interferon responses. Many cGAS-STING pathway agonists have been developed and tested in preclinical research for the treatment of cancer or infectious diseases with promising results. As adjuvants, cGAS-STING agonists have demonstrated their potential to activate robust defense immunity in various diseases, including COVID-19 infection. This review summarized the current developments in the field of cGAS-STING agonists with a special focus on the latest applications of cGAS-STING agonists as adjuvants in vaccination. Potential challenges were also discussed in the hope of sparking future research interests to further the development of cGAS-STING as vaccine adjuvants.
摘要：
佐剂在疫苗开发中具有关键价值,因为它们作用于增强抗原的免疫原性和诱导持久的免疫。然而,只有少数佐剂被批准用于临床，这凸显了探索和开发新的佐剂以满足日益增长的疫苗接种需求的必要性。最近,新出现的证据表明，cGAS-STING途径通过产生I型干扰素反应来协调先天和适应性免疫。已经开发了许多cGAS-STING途径激动剂,并在用于治疗癌症或感染性疾病的临床前研究中进行了测试,获得了有希望的结果。作为佐剂,cGAS-STING激动剂已证明其在各种疾病中激活强大的防御免疫的潜力，包括COVID-19感染。这篇综述总结了cGAS-STING激动剂领域的最新发展，特别关注cGAS-STING激动剂作为疫苗接种佐剂的最新应用。还讨论了潜在的挑战，希望激发未来的研究兴趣，以进一步开发cGAS-STING作为疫苗佐剂。
